Indium

Generic Name: Indium

Drug Type: Small Molecule

Chemical Formula: In

CAS Number: 7440-74-6

Unique Ingredient Identifier: 045A6V3VFX

Background: Indium has been used in trials studying the basic science of Clear Cell Renal Cell Carcinoma.

Clinical Trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Biological: Actinium Ac 225-DOTA-Daratumumab
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Biological: Daratumumab
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Hematopoietic Cell Transplantation
Biological: Indium In 111-DOTA-Daratumumab
Drug: Melphalan
Procedure: Multigated Acquisition Scan
Procedure: Radionuclide Imaging
Procedure: Single Photon Emission Computed Tomography
Drug: Sirolimus
Drug: Tacrolimus
Radiation: Total Marrow and Lymphoid Irradiation

First Posted Date: 2024-03-01

Last Posted Date: 2025-02-18

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT06287944

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1

Suspended

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: Actinium Ac 225-DOTA-Daratumumab
Biological: Daratumumab
Biological: Indium In 111-DOTA-Daratumumab

First Posted Date: 2022-05-05

Last Posted Date: 2025-05-01

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT05363111

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Basiliximab
Drug: Fludarabine Phosphate
Drug: Indium In 111-DOTA-Basiliximab
Drug: Melphalan
Biological: Palifermin
Radiation: Total Lymphoid Irradiation
Radiation: Total Marrow Irradiation
Biological: Yttrium Y 90 Basiliximab

First Posted Date: 2021-12-01

Last Posted Date: 2025-01-03

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 12

Registration Number: NCT05139004

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging

Phase 1

Completed

Conditions: Colonic Neoplasms

First Posted Date: 2005-09-16

Last Posted Date: 2016-04-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 42

Registration Number: NCT00185081

Locations: 🇳🇱
Radboud University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy